Nabilone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Nabilone: From Chemotherapy-Induced Nausea and Vomiting to Migraine Disorder
One-Sentence Summary
Nabilone is a synthetic cannabinoid (CB1/CB2 receptor agonist), historically used as an antiemetic for chemotherapy-induced nausea and vomiting refractory to standard antiemetics. The TxGNN model predicts it may be effective for Migraine Disorder, but at present no clinical trials and no publications directly support this specific indication — the signal derives solely from an algorithmic mechanistic hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chemotherapy-induced nausea and vomiting (CINV) refractory to standard antiemetics* |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
* No formal UK regulatory licence data is available in this evidence pack; this indication is inferred from a literature abstract referenced elsewhere in the dataset (PMID 37314117), not from an MHRA-approved indication text.
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not directly supplied for nabilone (flagged as a data gap). However, supporting literature within the evidence pack describes nabilone as a synthetic analogue of delta-9-tetrahydrocannabinol acting as an agonist at cannabinoid CB1 and CB2 receptors. On this basis, the TxGNN prediction rationale proposes that nabilone may act on the endocannabinoid system’s modulation of the trigeminovascular pathway — a mechanism theoretically shared between its known antiemetic activity and migraine pathophysiology.
This mechanistic hypothesis is plausible but entirely unproven for migraine disorder specifically: no clinical trials or peer-reviewed publications in this evidence pack evaluate nabilone in migraine. By contrast, a related indication in the same prediction set — headache disorder (rank 3, evidence level L3) — is supported by an actual randomised controlled trial in medication overuse headache (PMID 23070400), suggesting the underlying mechanistic hypothesis has some real-world grounding, even though it has not yet been tested in migraine itself.
Given the complete absence of direct evidence for migraine disorder, this prediction should currently be regarded as a hypothesis-generating signal rather than a therapeutically actionable finding.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No UK marketing authorisations are recorded for Nabilone in this evidence pack (total licences: 0; market status: Not marketed). Regulatory and licensing status should be independently confirmed with the MHRA before any further evaluation.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The migraine disorder prediction rests entirely on a TxGNN mechanistic hypothesis with no supporting clinical trials or literature, and nabilone currently has no UK marketing authorisation, documented MOA, or safety data on file — insufficient basis to proceed.
To proceed, the following is needed:
- Direct clinical trial or literature evidence specifically evaluating nabilone (not cannabinoids as a class) in migraine disorder
- Confirmed UK marketing authorisation status, dosage forms, and SmPC-derived warnings, contraindications and drug interactions
- Verified original indication and mechanism-of-action data from an authoritative source (e.g. DrugBank, MHRA)
Additional observation: Within the same prediction set, headache disorder (rank 3) carries stronger evidence — one Phase N/A trial and four publications, including an RCT in medication overuse headache (PMID 23070400) — and may warrant separate evaluation as a more actionable candidate than migraine disorder specifically.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.